DrugInfoSys

Olmesartan Medoxomil

Drug #1660

Olmesartan medoxomil is an antihypertensive agent, belongs to angiotensin II receptor antagonists. The actions, uses and adverse effects are similar to those of losartan. Olmesartan medoxomil is used either alone or in combination with other antihypertensive agents for the management of hypertension and other cardiovascular disorders.

← Previous drugNext drug →

Primary Characteristics

It is of Synthetic origin and belongs to Ester.

Molecular Weight: 558.59 · Non-proprietary name: Olmesartan Medoxomil.

Molecular structure of Olmesartan Medoxomil

Pharmacokinetics

Absorption: Olmesartan Medoxomil has an oral bioavailability is 42.5% (±7.5%).

Distribution: Olmesartan Medoxomil has a volume of distribution is 17L. plasma protein binding is 99%.

Elimination: it is metabolised via Hepatic, plasma half-life is 13 hrs, renal excretion is 35-50%.

Advertisement

Indications

Olmesartan Medoxomil is primarily indicated in conditions like Hypertension.

Olmesartan Medoxomil is also indicated for secondary conditions like Diabetic nephropathy, Heart failure.

Contraindications

Olmesartan Medoxomil is contraindicated in conditions like Hepatic impairment, Breast feeding, Dry or painful cough, Pain and inflammation (rheumatic disease).

Dosage

Olmesartan Medoxomil's dosage details are as follows:

DoseSingle DoseFrequencyRouteInstructions
Adult Dosage
10 – 20 mg—Every 24hPOFor patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan Medoxomil may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Olmesartan Medoxomil is known to cause more or less tolerable side effects which are usually transient. These include Angioedema, Back pain, Bronchitis , Diarrhea, Dizziness, Headache, Hematuria, Hyperglycemia, Hypotension , Pharyngitis, Pruritis, Rhinitis , Sinusitis .

Warnings / Precautions

Use with caution in renal artery stenosis, aortic or mitral valve stenosis and in obstructive hypertrophic cardiomyopathy.Monitor plasma-potassium concentration, particularly in elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients.

Interference in Pathology

Olmesartan Medoxomil may interfere in the diagnosis of Hematocrit Value , Liver Function Test (LFT) , Raised creatine phosphokinase, Elevated liver enzymes.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Tabs
10 mg20 mg40 mg5 mg

Multi-Ingredient Combinations

Tabs
10 mg20 mg40 mg5 mg

Storage Conditions

Olmesartan Medoxomil should be stored Tabs.

Drug Classification

  1. 1.12.3.4 — Angiotensin II receptor anatgonists

Manufacturers